Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Nicox SA (NICXF : OTC)
 
 • Company Description   
Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. By leveraging their proprietary expertise in nitric oxide (NO) donation and other technologies, they are developing an extensive portfolio of novel product candidates that target multiple ophthalmic conditions, including glaucoma. Their portfolio includes three programs in development including NCX 470 for intraocular pressure lowering, based on their proprietary NO-donating research platform and NCX 4251, a proprietary formulation of the well-established molecule fluticasone, for acute exacerbations of blepharitis. Their research activities are focused on novel future generation NO-donors including NO-donating phosphodiesterase-5 (PDE5) inhibitors and NO-donating soluble guanylate cyclase (sGC) stimulators (in partnership with Ironwood).

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.77 Daily Weekly Monthly
20 Day Moving Average: 40 shares
Shares Outstanding: (millions)
Market Capitalization: $ (millions)
Beta: 0.62
52 Week High: $5.10
52 Week Low: $1.77
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -4.32% 7.76%
12 Week -28.05% -20.89%
Year To Date -35.87% -21.64%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
Drakkar 2 - Batiment D 2405 route des Dolines - CS 10313 Sophia Antipolis Cedex
-
Valbonne,I0 06560
FRA
ph: 33-4-97-24-53-00
fax: 33-4-97-24-53-99
None http://www.nicox.com
 
 • General Corporate Information   
Officers
Michele Garufi - Chief Executive Officer and Chairman
Lauren Silvernail - Chief Financial Officer
Michael Bergamini - Executive Vice President
Sandrine Gestin - Director
Emmanuelle Pierry - Director

Peer Information
Nicox SA (CORR.)
Nicox SA (RSPI)
Nicox SA (CGXP)
Nicox SA (BGEN)
Nicox SA (GTBP)
Nicox SA (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: F6533F301
SIC: 8880
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding:
Most Recent Split Date: 12.00 (0.20:1)
Beta: 0.62
Market Capitalization: $ (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.17 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.52 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.54
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -
12/31/21 - -
09/30/21 - -
Current Ratio
03/31/22 - -
12/31/21 - -
09/30/21 - -
Quick Ratio
03/31/22 - -
12/31/21 - -
09/30/21 - -
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - -
12/31/21 - -
09/30/21 - -
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©